For example, tACS had little effect on scale scores and Abeta levels in AD patients, but led to an increase in gamma EEG power spectrum, an increase in cerebral blood flow, a decrease in p-Tau burden, and a decrease in microglial activation (Dhaynaut et al., 2022; Sprugnoli et al., 2021). Here, MAPT is linked to Alzheimer disease.